Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders??? Equity

v3.22.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Deficit
Beginning balance (in shares) at Dec. 31, 2020   24,883,024    
Beginning balance at Dec. 31, 2020 $ 95,250 $ 0 $ 164,264 $ (69,014)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss (13,765)     (13,765)
Founders earnout shares vested (in shares)   570,212    
Issuance of common shares upon vesting RSUs (in shares)   7,713    
Exercise of warrants (in shares)   122,639    
Exercise of warrants 1,410   1,410  
Stock-based compensation expense 1,550   1,550  
Ending balance (in shares) at Mar. 31, 2021   25,583,588    
Ending balance at Mar. 31, 2021 84,445 $ 0 167,224 (82,779)
Beginning balance (in shares) at Dec. 31, 2020   24,883,024    
Beginning balance at Dec. 31, 2020 95,250 $ 0 164,264 (69,014)
Ending balance (in shares) at Dec. 31, 2021   26,605,797    
Ending balance at Dec. 31, 2021 72,770 $ 0 187,510 (114,740)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss $ (16,140)     (16,140)
Issuance of common shares upon vesting RSUs (in shares)   247,453    
Stock option exercise (in shares) 123,300 116,112    
Stock option exercise $ 22   22  
Stock-based compensation expense 500   500  
Issuance of common stock - gross (in shares)   11,047,567    
Issuance of common stock - gross 23,400   23,400  
Equity issuance costs (1,177)   (1,177)  
Conversions of Convertible Note to common shares (in shares)   607,000    
Conversions of Convertible Note to common shares 1,324   1,324  
Beneficial conversion feature 1,749   1,749  
Ending balance (in shares) at Mar. 31, 2022   38,623,929    
Ending balance at Mar. 31, 2022 $ 82,448 $ 0 $ 213,328 $ (130,880)